These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3920706)

  • 1. The dexamethasone suppression and TRH stimulation tests in the initial phase of depression treatment.
    Escobar JI; Halaris A; Baxter L; Schwarcz G; Thompson M; Hurwicz ML; Hill M; Young M; Daugherty K; Clemens A
    Psychopharmacol Bull; 1985; 21(1):77-80. PubMed ID: 3920706
    [No Abstract]   [Full Text] [Related]  

  • 2. The correlation of dexamethasone suppression test and thyrotropin-releasing hormone test results in different subtypes of depression.
    D'Haenen H; Kaufman L; De Weert D; Cornet C; Raets I
    Acta Psychiatr Belg; 1984; 84(3):228-34. PubMed ID: 6435395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acute hospitalization on the dexamethasone suppression and TRH stimulation tests.
    Roy-Byrne P; Gwirtsman H; Sternbach H; Gerner RH
    Biol Psychiatry; 1984 Apr; 19(4):607-12. PubMed ID: 6428471
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroendocrine abnormalities in affective disorders.
    Extein I; Pottash AL; Gold MS
    Encephale; 1982; 8(2):203-11. PubMed ID: 6809445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine dysfunction and response to tricyclic antidepressants.
    Kirstein L
    J Clin Psychiatry; 1984 Sep; 45(9):385-6. PubMed ID: 6432772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression.
    Rush AJ; Giles DE; Schlesser MA; Orsulak PJ; Weissenburger JE; Fulton CL; Fairchild CJ; Roffwarg HP
    Biol Psychiatry; 1997 May; 41(9):915-28. PubMed ID: 9110097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biologic diagnosis of depression by the TRH and dexamethasone tests].
    Chabrol H; Moron P
    Encephale; 1983; 9(1):1-22. PubMed ID: 6135596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of serial neuroendocrine challenge studies in the management of depressive disorder.
    Targum SD
    Biol Psychiatry; 1983 Jan; 18(1):3-19. PubMed ID: 6403062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The specificity of the thyrotropin-releasing hormone (TRH) test and dexamethasone suppression test (DST) for major depressive illness in alcoholics.
    Dackis CA; Pottash AL; Bailey J; Stuckey RF; Extein IL; Gold MS
    NIDA Res Monogr; 1983 Apr; 43():266-72. PubMed ID: 6410260
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroendocrine predictors of the antidepressant effect of partial sleep deprivation.
    Joffe R; Brown P; Bienenstock A; Mitton J
    Biol Psychiatry; 1984 Mar; 19(3):347-52. PubMed ID: 6426532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse.
    Targum SD
    Biol Psychiatry; 1984 Mar; 19(3):305-18. PubMed ID: 6426529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships among the TRH, REM latency, and dexamethasone suppression tests: preliminary findings.
    Rush AJ; Schlesser MA; Roffwarg HP; Giles DE; Orsulak PJ; Fairchild C
    J Clin Psychiatry; 1983 Aug; 44(8 Pt 2):23-9. PubMed ID: 6409892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The dexamethasone suppression test and TRH stimulation test in endogenous depressives, schizophrenics, and normal volunteers].
    Ho SL; Lu RB; Ferng HK; Lin TY
    Zhonghua Yi Xue Za Zhi (Taipei); 1988 Apr; 41(4):271-80. PubMed ID: 3141027
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of biologic markers in a general hospital affective disorders program.
    Lieber AL; Newbury N
    J Clin Psychiatry; 1985 Jun; 46(6):217-21. PubMed ID: 3922959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. d-Amphetamine response and dexamethasone suppression test as predictors of treatment outcome in unipolar depression.
    Ettigi PG; Hayes PE; Narasimhachari N; Hamer RM; Goldberg S; Secord GJ
    Biol Psychiatry; 1983 Apr; 18(4):499-504. PubMed ID: 6860724
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients.
    Esel E; Kartalci S; Tutus A; Turan T; Sofuoglu S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):303-9. PubMed ID: 14751427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical psychiatry conference: biological and family indicators in depression.
    Baer RK; Muecke MM; Nasr S; Lahmeyer HW; Gaviria FM; Dysken MW; Akiskal HS; Dilsaver SC; Greden JF
    J Clin Psychiatry; 1983 Oct; 44(10):372-8. PubMed ID: 6417114
    [No Abstract]   [Full Text] [Related]  

  • 18. The dexamethasone suppression test in bulimia before and after successful treatment with desipramine.
    Hughes PL; Wells LA; Cunningham CJ
    J Clin Psychiatry; 1986 Oct; 47(10):515-7. PubMed ID: 3759916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of masked and endogenous depression using psychometric scales, endocrinological markers and pharmacological responses. Masked depression versus endogenous depression].
    Pinard G; Desmarais PA; Cormier H; Dymetryszyn R; Tétreault L
    Encephale; 1986; 12(3):99-103. PubMed ID: 3095093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dexamethasone suppression test in the identification subtypes of depression differentially responsive to antidepressants [proceedings].
    Brown WA; Haier RJ; Qualls CB
    Psychopharmacol Bull; 1981 Jan; 17(1):88-90. PubMed ID: 7232667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.